13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BMS CA209-7FL

    Acronym: 

    BMS CA209-7FL

    ACTRN/NCT /ethics: 

    Scientific title: 

    A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III Tumour Stream Breast
    Age Range 18 years and older Cancer Stage All stages
    Sex Female Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Breast
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

    Lay Summary

    A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary Central Districts Hospital Julie Rowe julie.rowe@calvarycare.org.au 9 8239 9536 Dr Rohit Joshi Not Yet Recruiting